<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789763</url>
  </required_header>
  <id_info>
    <org_study_id>GEMCAD 0701</org_study_id>
    <nct_id>NCT00789763</nct_id>
  </id_info>
  <brief_title>Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma</brief_title>
  <official_title>Open-label, Multicentric Phase I-II Trial to Evaluate the Efficacy and Safety of the Combination of Sorafenib (BAY 43-9006), Gemcitabine and Concurrent Radiotherapy, in Locally Advanced Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol Multidisciplinario del Cancer Digestivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol Multidisciplinario del Cancer Digestivo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I: Safety profile and to determine maximum tolerated dose (MTD) / Recommended Dose (DR)&#xD;
      of Sorafenib in combination with Gemcitabine and Radiotherapy&#xD;
&#xD;
      Phase II: Activity profile evaluating Progression-free rates (PFR) at 6 months, Response&#xD;
      rate, Overall survival, Toxicity profile&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety profile and to determine maximum tolerated dose (MTD) / Recommended Dose (DR) of&#xD;
      Sorafenib in combination with Gemcitabine and Radiotherapy&#xD;
&#xD;
      Definition of maximum tolerated dose (MTD):&#xD;
&#xD;
      The MTD is defined as the highest dose level which can be given to 6 patients such that no&#xD;
      more than 1 patient experiences a DLT .&#xD;
&#xD;
      Definition of Recommended Dose (DR):&#xD;
&#xD;
      Is the MTD&#xD;
&#xD;
      Definition of Dose-limiting toxicity (DLT):&#xD;
&#xD;
      DLT will be defined as any of the following occurring during the period of treatment and&#xD;
      regarded as related to the combination regimen.&#xD;
&#xD;
        -  Grade 4 thrombocytopenia persisting greater than 4 days, or with bleeding requiring&#xD;
           platelet transfusion&#xD;
&#xD;
        -  Grade 4 neutropenia lasting more than 7 days&#xD;
&#xD;
        -  Febrile neutropenia (≥ 38.5oC) with an absolute neutrophil count ≤ 1000/mm3&#xD;
&#xD;
        -  Any grade 3 or 4 non-hematologic toxicity related to the combination [occurring despite&#xD;
           optimal supportive care, if applicable] except hyperglycemia, hypoglycemia, deep venous&#xD;
           thrombosis, or hyperbilirubinemia secondary to stent malfunction.&#xD;
&#xD;
        -  Hypertension that is symptomatic and not managed by maximal use of three different&#xD;
           classes of antihypertensives, or any episode of malignancy hypertension&#xD;
&#xD;
      (Detailed Dose Modifications and G-CSF use in case of febrile neutropenia will be outlined in&#xD;
      the full protocol version)&#xD;
&#xD;
      Phase II&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      Activity profile evaluating Progression-free rates (PFR) at 6 months&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      Response rate Overall survival Toxicity profile&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAFETY</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EFFICACY</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TO DETERMINE MTD</measure>
    <time_frame>Treatment (5 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RESPONSE (ACCORDING TO RECIST)</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib + gemcitabine + radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>300 mg/m2/one per week, i.v., during 5 weeks.</description>
    <arm_group_label>Sorafenib + gemcitabine + radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)</description>
    <arm_group_label>Sorafenib + gemcitabine + radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>200-800 mg/day p.o. during 5 weeks</description>
    <arm_group_label>Sorafenib + gemcitabine + radiotherapy</arm_group_label>
    <other_name>Brand name: nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. -Patients with histological or cytological confirmed locally advanced pancreatic&#xD;
             adenocarcinoma pancreatic carcinoma or metastatic pancreatic carcinoma for phase I.&#xD;
&#xD;
          2. -Patients with measurable (according to RECIST) disease.&#xD;
&#xD;
          3. -Male or female patients &gt; or = 18 years old&#xD;
&#xD;
          4. -ECOG 0-1&#xD;
&#xD;
          5. -Adequate bone marrow, liver , and renal function: Absolute neutrophil count ( ANC) &gt;=&#xD;
             1,500/mm3 Platelets&gt; or = 100,000/µl Hemoglobin &gt;=9.0 g/dl Total bilirubin &lt; 1.5 x the&#xD;
             upper limit of normal. ALT and AST &lt;= 2.5 x upper limit of normal ( &lt;= 5X upper limit&#xD;
             of normal for patients with liver involvement ) Serum creatinine &lt;= 1.5 times x the&#xD;
             upper limit of normal. Patients with creatinine clearance &gt;= 45mL/min PT( prothrombin&#xD;
             time ) or INR( international normalized ratio ) and PTT ( partial thromboplastin time&#xD;
             ) &lt; =1.5 x&#xD;
&#xD;
          6. -Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (barrier method of birth control) prior to study entry and for the duration of study&#xD;
             participation. Men should use adequate birth control for at least six months after the&#xD;
             last administration of sorafenib&#xD;
&#xD;
          7. -Signed informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. -Patients with previous treatment for pancreatic carcinoma&#xD;
&#xD;
          2. -PTV ( planning target volume ) &gt;500 cm3 or 5 cm (maximum diameter)&#xD;
&#xD;
          3. -Patients with known or suspected allergy to iodated contrasts or renal impairment&#xD;
             which prevents from radiological tests.&#xD;
&#xD;
          4. -Pregnant or nursing patients. Women of childbearing potential must have a negative&#xD;
             serum pregnancy test performed within 7 days prior to the start of treatment&#xD;
&#xD;
          5. -General medical or psychological conditions that would preclude appropriate informed&#xD;
             consent or compliance with the protocol.&#xD;
&#xD;
          6. -Previous cancer that is distinct in primary site or histology from NSCLC except&#xD;
             cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors (Ta&#xD;
             and Tis) or any cancer curatively treated &gt; 3 years prior to study entry&#xD;
&#xD;
          7. -Concurrent treatment with other experimental drugs (within 30 days prior to study&#xD;
             entry).&#xD;
&#xD;
          8. -Concurrent treatment with other anti-cancer therapy.&#xD;
&#xD;
          9. -Therapeutic anticoagulation with Vitamin K antagonists such as warfarin or with&#xD;
             heparins or heparinoids. Low dose warfarin is permitted if INR is &lt;1.5 . Low dose&#xD;
             aspirin is permitted .&#xD;
&#xD;
         10. -Patients with any medical condition which could jeopardize their safety while his&#xD;
             participation in the study .&#xD;
&#xD;
         11. -Significant weight loss (&gt; or equal 10% body weight during preceding 6 weeks)&#xD;
&#xD;
         12. -Major surgery within 3 previous weeks, or laparoscopic biopsy or significant&#xD;
             traumatic injury within 2 weeks of prior to first dose of study drug.&#xD;
&#xD;
         13. -Known or suspected allergy to sorafenib or any agent given in the course of this&#xD;
             trial .&#xD;
&#xD;
         14. -Patients with evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
         15. -Thrombotic or embolic events such as cerebrovascular accident including transient&#xD;
             ischemic attacks within the past 6 months&#xD;
&#xD;
         16. -Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mm Hg or diastolic&#xD;
             pressure &gt; 90 mm Hg, despite optimal medical management&#xD;
&#xD;
         17. -Cardiac disease: Congestive heart failure &gt; class II NYHA. Patients must not have&#xD;
             unstable angina or new-onset angina (began within the last 3 months) or myocardial&#xD;
             infarction within the last 6 months&#xD;
&#xD;
         18. -Patients with Child-Pugh class C hepatic impairment&#xD;
&#xD;
         19. -Patients with severe renal impairment (calculated creatinine clearance of &lt; 30&#xD;
             ml/min) or who require dialysis&#xD;
&#xD;
         20. -Active clinically serious infections &gt; CTCAE Grade 2&#xD;
&#xD;
         21. -Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
         22. -Patients with concomitant ketoconazole, itraconazole,ritonavir,rifampicin or St.&#xD;
             John's Wort (Hypericum perforatum).&#xD;
&#xD;
         23. -Known brain metastasis. Patients with neurological symptoms should undergo a CT&#xD;
             scan/MRI of the brain to exclude brain metastasis&#xD;
&#xD;
         24. -Any instable condition that may interfere with the patients participation in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>Pancreatic cancer locally advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

